Antag (private company)

See something wrong or missing? Let us know
Offices:
Copenhagen
Business model:
B2B B2C (Retail)
Investors:
we tracked 1 investor
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Antag has developed a novel anti-obesity treatment based on a highly potent inhibitor of a hormone involved in fat accumulation.

Companies with similar profile to Antag:

CompanyCriteria
Sweden Scandinavian Real Hearts
55%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Sweden Athera
55%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Sweden Merozyne Therapeutics
46%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark Acesion Pharma
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Denmark Biosyntia
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Denmark Reapplix
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Sweden Bioservo Technologies
44%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Iceland Key Natura
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Finland Mobidiag
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Sweden Iconovo
44%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Sweden Monocl
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Norway Cytovation
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Finland Dispelix
44%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Finland WellO2
44%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
  • Total raised in a similar range: 1M - 5M USD
Denmark Oncology Venture
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Sweden AMRA
35%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Norway No Isolation
34%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
Finland Oura Health
34%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
Finland Lifted
34%
  • Similar verticals: Health services
  • Similar business models: B2B, B2C (Retail)
Finland Optomed
34%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B

News about Antag

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)